Drugs / ARI0003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06097455 | Jan 2024 → Apr 2025 overdue | non-Hodgkin lymphoma | Fundacion Clinic per a la Recerca Biomédica | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARI0003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06097455 ↗ |
| Route | Intravenous | “ARI0003 will be administered intravenously under a split regime.” NCT06097455 ↗ |
| Target | BCMA | “We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors” PMID 39563035 ↗ Nov 2024 |
| Target | CD19 | “We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors” PMID 39563035 ↗ Nov 2024 |